Alzheimer's disease, the most common form of dementia, is a chronic, progressive neurodegenerative disorder.i It is the fifth leading cause of death among people aged 65 years and older in the United States.i
Currently, about 5.5 million people in the United States are affected by Alzheimer's disease, and that number could triple in upcoming decades, rising to 16 million by 2050.i
In addition to the impact on quality of life for both patients and caregivers, Alzheimer's disease costs the United States $259 billion annually—nearly twice as much as cancer ($125 billion),i,ii and costs are expected to rise to an estimated $1.1 trillion by 2050.i
The main obstacle to progress in the fight against Alzheimer's disease has been the absence of drugs that are capable of slowing disease progression.iii No new chemical entities have been approved for the treatment of Alzheimer's disease since 2003.iv
- Alzheimer's Association. 2017 Alzheimer’s disease facts and figures. https://www.alz.org/documents_custom/2017-facts-and-figures.pdf. Accessed August 15 2017.
- Farina KL. The economics of cancer care in the United States. American Journal of Managed Care. http://www.ajmc.com/journals/evidence-based-oncology/2012/2012-2-vol18-n1/the-economics-of-cancer-care-in-the-united-states-how-much-do-we-spend-and-how-can-we-spend-it-better. Published March 16, 2012. Accessed August 15, 2017.
- Folch J, Petrov D, Ettcheto M, et al. Current research therapeutic strategies for Alzheimer's disease treatment. Neural Plast. 2016;2016:8501693. https://www.hindawi.com/journals/np/2016/8501693/. Published January 3, 2016. Accessed August 15, 2017.
- Cummings JL, Morstorf T, Zhong K. Alzheimer's disease drug-development pipeline: few candidates, frequent failures. Alzheimer Res Ther. 2014;6(4):37. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4095696/. Published July 3, 2014. Accessed August 15, 2017.